MX2014014109A - Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral. - Google Patents
Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.Info
- Publication number
- MX2014014109A MX2014014109A MX2014014109A MX2014014109A MX2014014109A MX 2014014109 A MX2014014109 A MX 2014014109A MX 2014014109 A MX2014014109 A MX 2014014109A MX 2014014109 A MX2014014109 A MX 2014014109A MX 2014014109 A MX2014014109 A MX 2014014109A
- Authority
- MX
- Mexico
- Prior art keywords
- useful
- viral disease
- pyrazolo
- amelioration
- dihydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650725P | 2012-05-23 | 2012-05-23 | |
| PCT/EP2013/060634 WO2013174931A1 (en) | 2012-05-23 | 2013-05-23 | 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014014109A true MX2014014109A (es) | 2016-03-31 |
Family
ID=48669866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014109A MX2014014109A (es) | 2012-05-23 | 2013-05-23 | Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130317021A1 (enExample) |
| EP (1) | EP2861232A1 (enExample) |
| JP (1) | JP2015521189A (enExample) |
| KR (1) | KR20150014506A (enExample) |
| CN (1) | CN104507481B (enExample) |
| BR (1) | BR112014029006A2 (enExample) |
| CA (1) | CA2874253A1 (enExample) |
| HK (1) | HK1204987A1 (enExample) |
| MX (1) | MX2014014109A (enExample) |
| RU (1) | RU2014146778A (enExample) |
| WO (1) | WO2013174931A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| US9434745B2 (en) * | 2012-05-23 | 2016-09-06 | Savira Pharmaceuticals Gmbh | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
| CN105980386B (zh) | 2013-03-13 | 2021-08-13 | 基因泰克公司 | 吡唑并化合物及其用途 |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| PL3077397T3 (pl) | 2013-12-06 | 2020-04-30 | Vertex Pharmaceuticals Inc. | Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne |
| SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
| AU2015284307A1 (en) | 2014-07-01 | 2017-02-02 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA2953862A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| EP4219508B1 (en) | 2015-04-28 | 2024-06-05 | Shionogi & Co., Ltd | Substituted polycyclic pyridone derivative and prodrug thereof |
| US20170081331A1 (en) * | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| CR20180356A (es) | 2015-12-15 | 2018-08-22 | Shionogi & Co | Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza |
| JP6957535B2 (ja) | 2016-06-29 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤 |
| NZ791086A (en) | 2016-08-10 | 2025-08-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| US20200048259A1 (en) * | 2016-10-12 | 2020-02-13 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| EP3525785B1 (en) * | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| JP2020533376A (ja) | 2017-09-15 | 2020-11-19 | アドゥロ バイオテック，インク． | ピラゾロピリミジノン化合物およびその使用 |
| EA202091835A1 (ru) * | 2018-01-31 | 2020-10-20 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv |
| CN113620977B (zh) * | 2021-08-24 | 2024-02-02 | 江苏弘和药物研发有限公司 | 一种噻唑烷并嘧啶酮乙酸的合成方法 |
| CN117304133A (zh) * | 2023-09-26 | 2023-12-29 | 华南农业大学 | 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| EP1511751B1 (en) * | 2002-06-04 | 2008-03-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents |
| JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| WO2007146813A2 (en) * | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Pyridinone analogs as cell proliferation inhibitors |
| EP2412708A4 (en) | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| CN101671336B (zh) * | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| US9434745B2 (en) * | 2012-05-23 | 2016-09-06 | Savira Pharmaceuticals Gmbh | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
-
2013
- 2013-05-23 KR KR1020147035547A patent/KR20150014506A/ko not_active Withdrawn
- 2013-05-23 CN CN201380025121.5A patent/CN104507481B/zh not_active Expired - Fee Related
- 2013-05-23 RU RU2014146778A patent/RU2014146778A/ru not_active Application Discontinuation
- 2013-05-23 JP JP2015513183A patent/JP2015521189A/ja active Pending
- 2013-05-23 MX MX2014014109A patent/MX2014014109A/es unknown
- 2013-05-23 EP EP13730131.3A patent/EP2861232A1/en not_active Withdrawn
- 2013-05-23 BR BR112014029006A patent/BR112014029006A2/pt not_active IP Right Cessation
- 2013-05-23 CA CA2874253A patent/CA2874253A1/en not_active Abandoned
- 2013-05-23 WO PCT/EP2013/060634 patent/WO2013174931A1/en not_active Ceased
- 2013-05-23 HK HK15105893.0A patent/HK1204987A1/xx unknown
- 2013-05-23 US US13/900,940 patent/US20130317021A1/en not_active Abandoned
-
2016
- 2016-06-24 US US15/191,865 patent/US20160367557A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130317021A1 (en) | 2013-11-28 |
| CA2874253A1 (en) | 2013-11-28 |
| CN104507481A (zh) | 2015-04-08 |
| BR112014029006A2 (pt) | 2017-06-27 |
| US20160367557A1 (en) | 2016-12-22 |
| HK1204987A1 (en) | 2015-12-11 |
| RU2014146778A (ru) | 2016-07-10 |
| EP2861232A1 (en) | 2015-04-22 |
| WO2013174931A1 (en) | 2013-11-28 |
| JP2015521189A (ja) | 2015-07-27 |
| CN104507481B (zh) | 2017-08-04 |
| KR20150014506A (ko) | 2015-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014014109A (es) | Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MX2014003803A (es) | Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| IN2014CN00989A (enExample) | ||
| EA201290237A1 (ru) | Киназные ингибиторы | |
| WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
| IN2014KN00948A (enExample) | ||
| MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| IN2015MN00002A (enExample) | ||
| PH12014500883A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| SG11201408052WA (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| MX2021005207A (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida. | |
| EP4582424A3 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| WO2013177349A3 (en) | Quinazolinediones as tankyrase inhibitors | |
| MX2015008292A (es) | Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| WO2008109856A3 (en) | Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions |